NEW YORK--(BUSINESS WIRE)--Feb. 16, 2006--ImClone Systems Incorporated (NASDAQ: IMCL) today announced that full patient enrollment has been completed in three international, registrational Phase III clinical trials examining the use of ERBITUX(R) (cetuximab) in three major cancer types. The first of these studies, known as EPIC, examines the use of ERBITUX in metastatic colorectal cancer after failure of oxaliplatin-based chemotherapy. The second, EXTREME, sponsored by Merck KGaA, examines ERBITUX as a first-line treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The third study, FLEX, also sponsored by Merck KGaA, explores the first-line use of ERBITUX in advanced non-small cell lung cancer. A combined total of more than 2,800 patients have been enrolled in these studies.
